Anzeige

Archive

Successful in vivo propagation of factor IX-producing hepatocytes in mice: Potential for cell-based therapy in haemophilia B

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
Topic:

Current use of biologicals in thrombosis and haemostasis

DOI: https://doi.org/10.1160/TH07-09-0559
Issue: 2008: 99/5 (May) pp. 799-983
Pages: 883-891

Successful in vivo propagation of factor IX-producing hepatocytes in mice: Potential for cell-based therapy in haemophilia B

Kohei Tatsumi 1, Kazuo Ohashi 2, 5, Miho Kataoka 3, Chise Tateno 3, #, Masaru Shibata 1, Hiroyuki Naka 1, Midori Shima 1, Michiyoshi Hisanaga 2, Hiromichi Kanehiro 2, Teruo Okano 5, Katsutoshi Yoshizato 3, 4, #, Yoshiyuki Nakajima 2, Akira Yoshioka1
1 Department of Pediatrics, Nara Medical University, Nara, Japan; 2 Department of Surgery, Nara Medical University, Nara, Japan; 3 Yoshizato Project, Cooperative Link of Unique Science and Technology for Economy Revitalization (CLUSTER), Hiroshima Prefectural Institute of Industrial Science and Technology, Hiroshima, Japan; 4 Graduate School of Science, Hiroshima University, Hiroshima, Japan; 5 Institute of Advanced Biomedical Engineering and Science, Tokyo Women's Medical University, Tokyo, Japan

Keywords

Haemophilia A/B, Coagulation factors, hepatology, haemophilia therapy

Summary

Cell-based therapies using isolated hepatocytes have been proposed to be an attractive application in the treatment of haemophilia B due to the normal production of coagulation factor IX (FIX) in these particular cells. Current cell culture technologies have largely failed to provide adequate isolated hepatocytes, so the present studies were designed to examine a new approach to efficiently proliferate hepatocytes that can retain normal biological function, including the ability to synthesize coagulation factors like FIX. Canine or human primary hepatocytes were transplanted into urokinase-type plasminogen activatorsevere combined immunodeficiency (uPA/SCID) transgenic mice. Both donor hepatocytes from canines and humans were found to progressively proliferate in the recipient mouse livers as evidenced by a sharp increase in the circulating blood levels of species-specific albumin, which was correlated with the production and release of canine and human FIX antigen levels into the plasma. Histological examination confirmed that the transplanted canine and human hepatocytes were able to proliferate and occupy >80% of the host livers. In addition, the transplanted hepatocytes demonstrated strong cytoplasmic staining for human FIX, and the secreted coagulation factor IX was found to be haemostatically competent using specific procoagulant assays. In all, the results from the present study indicated that developments based on this technology could provide sufficient FIX-producing hepatocytes for cell-based therapy for haemophilia B.

You may also be interested in...

1.

Online Supplementary Material

T. Kitazawa (1), K. Esaki (2), T. Tachibana (1), S. Ishii (2), T. Soeda (2), A. Muto (2), Y. Kawabe (2), T. Igawa (2), H. Tsunoda (1), K. Nogami (3), M. Shima (3), K. Hattori (1)

Thromb Haemost 2017 117 7: 1348-1357

https://doi.org/10.1160/TH17-01-0030

2.

C.-Y. Kao (1), S.-J. Yang (1), M.-H. Tao (2), Y.-M. Jeng (3, 4), I.-S. Yu (1), S.-W. Lin (1, 5)

Thromb Haemost 2013 110 2: 244-256

https://doi.org/10.1160/TH13-02-0154

3.

T. Livnat (1), U. Martinowitz (1), A. Zivelin (1), D. Rima (1), G. Kenet (1)

Thromb Haemost 2011 105 4: 688-695

https://doi.org/10.1160/TH10-08-0542